Viking Therapeutics (VKTX) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Share on StockTwits

Viking Therapeutics (NASDAQ:VKTX) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.03, Morningstar.com reports.

Shares of VKTX stock opened at $7.72 on Friday. Viking Therapeutics has a one year low of $3.69 and a one year high of $24.00. The company has a market capitalization of $570.25 million, a P/E ratio of -9.77 and a beta of 2.73.

Several research firms have recently issued reports on VKTX. Raymond James lowered their price objective on Viking Therapeutics from $43.00 to $40.00 and set a “strong-buy” rating for the company in a research note on Thursday. William Blair reiterated an “outperform” rating on shares of Viking Therapeutics in a report on Thursday. Maxim Group reduced their target price on Viking Therapeutics from $28.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday. BidaskClub cut Viking Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, March 6th. Finally, Leerink Swann initiated coverage on Viking Therapeutics in a report on Friday, February 22nd. They issued a “market perform” rating and a $10.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $22.88.

Several institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its holdings in shares of Viking Therapeutics by 30.6% during the 4th quarter. Geode Capital Management LLC now owns 594,510 shares of the biotechnology company’s stock worth $4,548,000 after buying an additional 139,420 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in Viking Therapeutics in the 4th quarter valued at $1,478,000. UBS Oconnor LLC raised its position in Viking Therapeutics by 8.3% in the 4th quarter. UBS Oconnor LLC now owns 102,842 shares of the biotechnology company’s stock valued at $787,000 after buying an additional 7,842 shares during the last quarter. HRT Financial LLC purchased a new stake in Viking Therapeutics in the 4th quarter valued at $349,000. Finally, Macquarie Group Ltd. raised its position in Viking Therapeutics by 16.2% in the 4th quarter. Macquarie Group Ltd. now owns 437,900 shares of the biotechnology company’s stock valued at $3,350,000 after buying an additional 61,100 shares during the last quarter. Hedge funds and other institutional investors own 65.69% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Viking Therapeutics (VKTX) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS” was first published by Week Herald and is owned by of Week Herald. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://weekherald.com/2019/03/15/viking-therapeutics-vktx-posts-quarterly-earnings-results-beats-estimates-by-0-03-eps.html.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

See Also: Diversification Important in Investing

Earnings History for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.